Tango Therapeutics is a cancer therapeutics company discovering and developing novel medicines designed to target cancer vulnerabilities beyond mutated oncogenes to deliver transformational new therapies for patients. The company uses deep DNA sequencing and CRISPR-based screening to identify targets for specific subgroups of cancer patients. Tango Therapeutics goal is to leverage the principles of synthetic lethality to find the weaknesses in cancer cells created by the genetic complexity and use them to provide a roadmap to cures.
|HQ||Cambridge, MA, US||Map|
|Employees (est.) (Jul 2021)||95||(+3%)|
Tango Therapeutics total Funding
Tango Therapeutics latest funding size
Time since last funding
|a year ago|
Tango Therapeutics investors
|Third Rock Ventures, Casdin Capital, Boxer Capital, Cormorant Asset Management, Gilead Sciences, Boxer Capital (Tavistock Group)|
When was Tango Therapeutics founded?
Tango Therapeutics was founded in 2017.
Who are Tango Therapeutics key executives?
Tango Therapeutics's key executives are Barbara Weber, Alan Huang and Daniella Beckman.
How many employees does Tango Therapeutics have?
Tango Therapeutics has 95 employees.
Who are Tango Therapeutics competitors?
Competitors of Tango Therapeutics include Beacon Discovery, Circle Pharma and Pepscan.
Where is Tango Therapeutics headquarters?
Tango Therapeutics headquarters is located at 100 Binney St #700, Cambridge.
Where are Tango Therapeutics offices?
Tango Therapeutics has an office in Cambridge.
How many offices does Tango Therapeutics have?
Tango Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies